Investigating the efficacy of paroxetine in developmental stuttering.

abstract：:Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

journal_title：Clinical neuropharmacology

authors： Rajput AH,Rozdilsky B,Rajput A,Ang L

更新日期：1990-12-01 00:00:00

abstract：:Five of 24 (21%) normal men (volunteers) administered alpha-methyl-para-tyrosine (AMPT), a catecholamine-depleting agent, developed acute dystonic reactions. The finding that catecholamine depletion without receptor blockade is sufficient to cause acute dystonia suggests that a variety of neurotransmitter imbalances m...

journal_title：Clinical neuropharmacology

authors： McCann UD,Penetar DM,Belenky G

更新日期：1990-12-01 00:00:00

abstract：OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...

journal_title：Clinical neuropharmacology

authors： Kim SW,Shin IS,Kim JM,Bae KY,Yang SJ,Yoon JS

更新日期：2010-05-01 00:00:00

abstract：:Intravenous injection of low doses of naloxone was found to reverse the respiratory depression induced by apomorphine in chloralose-anesthesized dogs. Similar results were obtained with haloperidol, whereas yohimbine remained ineffective. These data suggest that apomorphine depresses respiratory rate through a mechani...

journal_title：Clinical neuropharmacology

authors： Montastruc JL,Rascol O,Montastruc P

更新日期：1992-10-01 00:00:00

abstract：:The suppressive roles of adrenergic stimulation and rapid eye movement (REM) sleep on human prolactin (PRL) secretion are controversial. We examined the effects of sleep, clonidine (an alpha 2-adrenergic agonist), and their interaction on PRL secretion. Two groups of normal men (nine each) were studied in two morning ...

journal_title：Clinical neuropharmacology

authors： Cavallo A,Carskadon MA,Grocer P

更新日期：1991-10-01 00:00:00

abstract：:Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

journal_title：Clinical neuropharmacology

authors： Malizia AL,Nutt DJ

更新日期：1995-06-01 00:00:00

abstract：:Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetin...

journal_title：Clinical neuropharmacology

authors： Fukui H,Murai T

更新日期：2002-09-01 00:00:00

abstract：:The aim of this study was to assess the growth hormone (GH) axis in methylphenidate (MPH)-treated and untreated boys with attention-deficit and hyperactivity disorder (ADHD), by evaluating serum GH, GH-binding protein (GHBP) activity, and insulin-like growth factor I (IGF-I) levels as compared to age-matched normal co...

journal_title：Clinical neuropharmacology

authors： Toren P,Silbergeld A,Eldar S,Laor N,Wolmer L,Koren S,Weitz R,Inbar D,Reiss A,Eshet R,Weizman R

更新日期：1997-06-01 00:00:00

abstract：:Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepa...

journal_title：Clinical neuropharmacology

authors： Schachter SC

更新日期：1999-11-01 00:00:00

abstract：:Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...

journal_title：Clinical neuropharmacology

authors： Oulis P,Nakkas G,Masdrakis VG

更新日期：2011-03-01 00:00:00

abstract：:Twelve-hour urinary excretion of 4-hydroxy-3-methoxymandelic acid (VMA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) was studied in 20 premature infants, 8 without apnea and 12 with apnea. All infants were studied at 1-3 days of postnatal age (before apnea). Nonapneic infants were restudied at ...

journal_title：Clinical neuropharmacology

authors： Bhat AM,Scanlon JW,Lavenstein B,Chuang L,Karoum F

更新日期：1982-12-01 00:00:00

abstract：OBJECTIVE:Use of antipsychotic agents in the management of various psychopathologies in Child and Adolescent Psychiatric practice is gradually increasing. This study aimed to evaluate the sociodemographic and clinical features of children and adolescents who applied to an outpatient clinic of child and adolescent psych...

journal_title：Clinical neuropharmacology

authors： Yektaş Ç,Tufan AE

更新日期：2018-01-01 00:00:00

abstract：:The present study was carried out in order to verify whether, in benzodiazepine-medicated healthy volunteers, oxiracetam retained the properties already observed after administration in normal volunteers. In a cross-over study, 12 volunteers, medicated the night before with 5 mg diazepam, were i.v. treated with 1 g ox...

journal_title：Clinical neuropharmacology

authors： Giaquinto S,Nolfe G,Vitali S

更新日期：1986-01-01 00:00:00

abstract：OBJECTIVES:Neurosyphilis, an infectious neuroinflammatory disorder, could cause diverse neuropsychiatric symptoms mimicking disorders of schizophrenia and dementia; hence, it is known as the "chameleon of psychiatry." Here, we present a subject with neurosyphilis with schizophrenic features and share the treatment outc...

journal_title：Clinical neuropharmacology

authors： Chen WC,Wang HY,Chen PA,Chen IC,Chen YC

更新日期：2019-07-01 00:00:00

abstract：:Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Long KD,Gaskins B,Mastropaolo J

更新日期：2006-11-01 00:00:00

abstract：:The aim of the present study was to evaluate sexual function and behaviour in male patients who take lithium. Participants included 35 bipolar and schizoaffective men, aged 43.3 +/- 9.6 years, who were in euthymic state and were receiving lithium as the sole medical treatment. Eleven patients (31.4%) reported sexual d...

journal_title：Clinical neuropharmacology

authors： Aizenberg D,Sigler M,Zemishlany Z,Weizman A

更新日期：1996-12-01 00:00:00

abstract：OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

journal_title：Clinical neuropharmacology

authors： Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

更新日期：2005-09-01 00:00:00

abstract：:Fifty-six chronic schizophrenic patients were randomized into haloperidol decanoate (HD) or placebo groups for 48 weeks of double-blind treatment. The double-blind trial was preceded by a 15-week single-blind run-in period, during which all patients were treated with 60 mg of HD (approximately corresponding to 3.6 mg ...

journal_title：Clinical neuropharmacology

authors： Eklund K,Forsman A

更新日期：1991-01-01 00:00:00

abstract：:Palinopsia is an illusory visual phenomenon consisting in the persistence or recurrence of visual images after the exciting stimulus object has been removed. It has been reported in association with parietal and occipital lobe lesions, migraine auras, and related to the use of several drugs and illicit drugs. Here, we...

journal_title：Clinical neuropharmacology

authors： Sierra-Hidalgo F,de Pablo-Fernández E

更新日期：2013-03-01 00:00:00

abstract：OBJECTIVE:A multicenter open-label clinical trial was conducted to evaluate the clinical usefulness of topiramate (TPM) as primary or adjunctive therapy for infantile spasms in the postmarketing period in China. METHODS:Thirty-four centers participated in the trial. Patients included in the study had 1 or more seizure...

journal_title：Clinical neuropharmacology

authors： Zou LP,Lin Q,Qin J,Cai FC,Liu ZS,Mix E,Topiramate Study Group.

更新日期：2008-03-01 00:00:00

abstract：OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

journal_title：Clinical neuropharmacology

authors： Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

更新日期：2015-01-01 00:00:00

abstract：:Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...

journal_title：Clinical neuropharmacology

authors： Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

更新日期：1984-01-01 00:00:00

abstract：:A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

journal_title：Clinical neuropharmacology

authors： Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

更新日期：2008-05-01 00:00:00

abstract：:Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...

journal_title：Clinical neuropharmacology

authors： González de la Aleja J,Saiz-Díaz RA,De la Peña P

更新日期：2012-09-01 00:00:00

abstract：:The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

更新日期：1994-02-01 00:00:00

abstract：:Interferon (IFN) is the most widely prescribed drug of choice for chronic hepatitis B infection, which is a common health problem in our country. Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders. In this case report,...

journal_title：Clinical neuropharmacology

authors： Atasoy N,Ustundag Y,Konuk N,Atik L

更新日期：2004-05-01 00:00:00

abstract：:Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, fo...

journal_title：Clinical neuropharmacology

authors： Fernandez HH,Chen JJ

更新日期：2007-05-01 00:00:00

abstract：BACKGROUND:Negative myoclonus is rarely seen in the clinical setting. It can be involved in some central nervous system pathologies. It has also been observed after antipsychotic treatment. CASE REPORTS:In this article, we will present 3 cases diagnosed with negative myoclonus in a 120-bed university-affiliated hospit...

journal_title：Clinical neuropharmacology

authors： Uzun Ö,Bolu A,Taşçi AB,Oğur B

更新日期：2020-01-01 00:00:00

abstract：:Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importanc...

journal_title：Clinical neuropharmacology

authors： Greenamyre JT

更新日期：2001-03-01 00:00:00

abstract：OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

journal_title：Clinical neuropharmacology

authors： Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

更新日期：2010-01-01 00:00:00